TP53 and breast cancer: We found that DGI markedly differed between breast cancer GEMMs (P<10−16, χ2-test of independence), with the prevalence of large CNAs ranging from ∼4% to ∼80% of the tumours (>17-fold difference, for the PyMT and p53−/− models, respectively; Fig. 3a).